An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Sponsor
Aragon Pharmaceuticals, Inc.
Study ID
NCT03523338
Status
No Longer Available

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apalutamide — DRUG
    Participants will receive apalutamide 240 mg orally once daily.
  • ADT (Standard of Care) — DRUG
    Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.

Study Details

The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).

Key Dates

Status verified
Dec 2025

Related Studies